Titre : Lèpre

Lèpre : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Lèpre : Questions médicales les plus fréquentes", "headline": "Lèpre : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Lèpre : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-09", "dateModified": "2025-04-04", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Lèpre" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Infections à mycobactéries non tuberculeuses", "url": "https://questionsmedicales.fr/mesh/D009165", "about": { "@type": "MedicalCondition", "name": "Infections à mycobactéries non tuberculeuses", "code": { "@type": "MedicalCode", "code": "D009165", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.150.252.410.040.552.475" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lèpre multibacillaire", "alternateName": "Leprosy, Multibacillary", "url": "https://questionsmedicales.fr/mesh/D056006", "about": { "@type": "MedicalCondition", "name": "Lèpre multibacillaire", "code": { "@type": "MedicalCode", "code": "D056006", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.150.252.410.040.552.475.371.775" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lèpre lépromateuse", "alternateName": "Leprosy, Lepromatous", "url": "https://questionsmedicales.fr/mesh/D015440", "about": { "@type": "MedicalCondition", "name": "Lèpre lépromateuse", "code": { "@type": "MedicalCode", "code": "D015440", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.150.252.410.040.552.475.371.775.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Lèpre paucibacillaire", "alternateName": "Leprosy, Paucibacillary", "url": "https://questionsmedicales.fr/mesh/D056005", "about": { "@type": "MedicalCondition", "name": "Lèpre paucibacillaire", "code": { "@type": "MedicalCode", "code": "D056005", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.150.252.410.040.552.475.371.850" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lèpre interpolaire", "alternateName": "Leprosy, Borderline", "url": "https://questionsmedicales.fr/mesh/D015439", "about": { "@type": "MedicalCondition", "name": "Lèpre interpolaire", "code": { "@type": "MedicalCode", "code": "D015439", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.150.252.410.040.552.475.371.850.249" } } }, { "@type": "MedicalWebPage", "name": "Lèpre tuberculoïde", "alternateName": "Leprosy, Tuberculoid", "url": "https://questionsmedicales.fr/mesh/D015441", "about": { "@type": "MedicalCondition", "name": "Lèpre tuberculoïde", "code": { "@type": "MedicalCode", "code": "D015441", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.150.252.410.040.552.475.371.850.500" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Lèpre", "alternateName": "Leprosy", "code": { "@type": "MedicalCode", "code": "D007918", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Euzenir Nunes Sarno", "url": "https://questionsmedicales.fr/author/Euzenir%20Nunes%20Sarno", "affiliation": { "@type": "Organization", "name": "Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil." } }, { "@type": "Person", "name": "Wim H van Brakel", "url": "https://questionsmedicales.fr/author/Wim%20H%20van%20Brakel", "affiliation": { "@type": "Organization", "name": "NLR, Amsterdam, Netherlands." } }, { "@type": "Person", "name": "Tarun Narang", "url": "https://questionsmedicales.fr/author/Tarun%20Narang", "affiliation": { "@type": "Organization", "name": "Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India." } }, { "@type": "Person", "name": "Sunil Dogra", "url": "https://questionsmedicales.fr/author/Sunil%20Dogra", "affiliation": { "@type": "Organization", "name": "Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India." } }, { "@type": "Person", "name": "Mariana Andrea Hacker", "url": "https://questionsmedicales.fr/author/Mariana%20Andrea%20Hacker", "affiliation": { "@type": "Organization", "name": "Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil. marianah@ioc.fiocruz.br." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.", "datePublished": "2023-12-07", "url": "https://questionsmedicales.fr/article/38062182", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00464-023-10589-7" } }, { "@type": "ScholarlyArticle", "name": "[Translated article] Clinical and Epidemiological Characteristics of Patients Being Treated for Scabies in Spain: Opportunities for Improvement - A Multicenter Cross-Sectional CLINI-AEDV Study.", "datePublished": "2023-11-03", "url": "https://questionsmedicales.fr/article/37923079", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ad.2023.10.037" } }, { "@type": "ScholarlyArticle", "name": "Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy: multicenter retrospective cohort study.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/37830943", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/JS9.0000000000000621" } }, { "@type": "ScholarlyArticle", "name": "Incidence, risk factors and outcome of acute kidney injury in critically ill COVID-19 patients in Tyrol, Austria: a prospective multicenter registry study.", "datePublished": "2023-10-14", "url": "https://questionsmedicales.fr/article/37837501", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40620-023-01760-3" } }, { "@type": "ScholarlyArticle", "name": "Artificial intelligence-enhanced 12-lead electrocardiography for identifying atrial fibrillation during sinus rhythm (AIAFib) trial: protocol for a multicenter retrospective study.", "datePublished": "2023-10-11", "url": "https://questionsmedicales.fr/article/37886735", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fcvm.2023.1258167" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Infection", "item": "https://questionsmedicales.fr/mesh/D007239" }, { "@type": "ListItem", "position": 3, "name": "Infections bactériennes et mycoses", "item": "https://questionsmedicales.fr/mesh/D001423" }, { "@type": "ListItem", "position": 4, "name": "Infections bactériennes", "item": "https://questionsmedicales.fr/mesh/D001424" }, { "@type": "ListItem", "position": 5, "name": "Infections bactériennes à Gram positif", "item": "https://questionsmedicales.fr/mesh/D016908" }, { "@type": "ListItem", "position": 6, "name": "Infections à Actinomycetales", "item": "https://questionsmedicales.fr/mesh/D000193" }, { "@type": "ListItem", "position": 7, "name": "Infections à Mycobacterium", "item": "https://questionsmedicales.fr/mesh/D009164" }, { "@type": "ListItem", "position": 8, "name": "Infections à mycobactéries non tuberculeuses", "item": "https://questionsmedicales.fr/mesh/D009165" }, { "@type": "ListItem", "position": 9, "name": "Lèpre", "item": "https://questionsmedicales.fr/mesh/D007918" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Lèpre - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Lèpre", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Lèpre", "description": "Comment diagnostique-t-on la lèpre ?\nQuels tests sont utilisés pour la lèpre ?\nLa lèpre est-elle contagieuse ?\nQuels signes cliniques indiquent la lèpre ?\nPeut-on détecter la lèpre par des analyses sanguines ?", "url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Lèpre", "description": "Quels sont les symptômes de la lèpre ?\nLa lèpre cause-t-elle des douleurs ?\nLes lésions de la lèpre sont-elles douloureuses ?\nComment évoluent les symptômes de la lèpre ?\nPeut-on avoir des symptômes sans être contagieux ?", "url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Lèpre", "description": "Comment prévenir la lèpre ?\nLes vaccins protègent-ils contre la lèpre ?\nFaut-il éviter les personnes atteintes de lèpre ?\nQuelles mesures de santé publique sont prises ?\nLa lèpre est-elle une maladie évitable ?", "url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Lèpre", "description": "Quel est le traitement de la lèpre ?\nLa lèpre peut-elle être guérie ?\nCombien de temps dure le traitement de la lèpre ?\nY a-t-il des effets secondaires au traitement ?\nLe traitement de la lèpre est-il gratuit ?", "url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Lèpre", "description": "Quelles sont les complications de la lèpre ?\nLa lèpre peut-elle entraîner des handicaps ?\nLes complications sont-elles réversibles ?\nComment gérer les complications de la lèpre ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Lèpre", "description": "Qui est à risque de développer la lèpre ?\nL'immunité joue-t-elle un rôle dans la lèpre ?\nLes enfants sont-ils plus à risque ?\nLe statut socio-économique influence-t-il le risque ?\nLes personnes immunodéprimées sont-elles plus vulnérables ?", "url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la lèpre ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et des tests cutanés pour détecter les bacilles." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour la lèpre ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de sensibilité cutanée et des biopsies peuvent être réalisés pour confirmer la lèpre." } }, { "@type": "Question", "name": "La lèpre est-elle contagieuse ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La lèpre n'est pas très contagieuse; elle se propage par contact prolongé avec une personne infectée." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent la lèpre ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des lésions cutanées, des engourdissements et des déformations peuvent indiquer la lèpre." } }, { "@type": "Question", "name": "Peut-on détecter la lèpre par des analyses sanguines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les analyses sanguines ne sont pas spécifiques; le diagnostic repose principalement sur l'examen clinique." } }, { "@type": "Question", "name": "Quels sont les symptômes de la lèpre ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des lésions cutanées, des engourdissements et des douleurs nerveuses." } }, { "@type": "Question", "name": "La lèpre cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la lèpre peut provoquer des douleurs nerveuses et des sensations anormales." } }, { "@type": "Question", "name": "Les lésions de la lèpre sont-elles douloureuses ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les lésions cutanées sont souvent indolores, mais peuvent s'infecter et causer des douleurs." } }, { "@type": "Question", "name": "Comment évoluent les symptômes de la lèpre ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent évoluer lentement, avec des périodes d'aggravation et d'amélioration." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans être contagieux ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une personne peut avoir des symptômes sans être contagieuse, surtout en début d'infection." } }, { "@type": "Question", "name": "Comment prévenir la lèpre ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention repose sur le dépistage précoce et le traitement des personnes infectées." } }, { "@type": "Question", "name": "Les vaccins protègent-ils contre la lèpre ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de vaccin spécifique contre la lèpre, mais des recherches sont en cours." } }, { "@type": "Question", "name": "Faut-il éviter les personnes atteintes de lèpre ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Non, avec un traitement, les personnes atteintes ne sont plus contagieuses et peuvent être approchées." } }, { "@type": "Question", "name": "Quelles mesures de santé publique sont prises ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des campagnes de sensibilisation et de dépistage sont mises en place pour contrôler la lèpre." } }, { "@type": "Question", "name": "La lèpre est-elle une maladie évitable ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la lèpre est évitable grâce à un diagnostic précoce et un traitement adéquat." } }, { "@type": "Question", "name": "Quel est le traitement de la lèpre ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement standard est une polychimiothérapie (PCT) avec des antibiotiques comme la rifampicine." } }, { "@type": "Question", "name": "La lèpre peut-elle être guérie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la lèpre est curable avec un traitement approprié et précoce." } }, { "@type": "Question", "name": "Combien de temps dure le traitement de la lèpre ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement dure généralement de 6 mois à 2 ans, selon la forme de la maladie." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires au traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires peuvent survenir, mais ils sont généralement légers et gérables." } }, { "@type": "Question", "name": "Le traitement de la lèpre est-il gratuit ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Dans de nombreux pays, le traitement de la lèpre est gratuit et accessible." } }, { "@type": "Question", "name": "Quelles sont les complications de la lèpre ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions nerveuses, des déformations et des infections secondaires." } }, { "@type": "Question", "name": "La lèpre peut-elle entraîner des handicaps ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des lésions nerveuses peuvent causer des handicaps permanents si non traitées." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement précoce, d'autres non." } }, { "@type": "Question", "name": "Comment gérer les complications de la lèpre ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical et des soins adaptés aux lésions." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Qui est à risque de développer la lèpre ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes vivant dans des zones endémiques et celles en contact avec des malades sont à risque." } }, { "@type": "Question", "name": "L'immunité joue-t-elle un rôle dans la lèpre ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une immunité affaiblie augmente le risque de développer la lèpre." } }, { "@type": "Question", "name": "Les enfants sont-ils plus à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les enfants peuvent être à risque, mais la maladie touche principalement les adultes." } }, { "@type": "Question", "name": "Le statut socio-économique influence-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un faible statut socio-économique est associé à un risque accru de lèpre." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles plus vulnérables ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées ont un risque accru de contracter la lèpre." } } ] } ] }

Sources (10000 au total)

Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.

The latest Barcelona Clinic Liver Cancer (BCLC) staging system suggests considering surgery in patients with resectable BCLC stage 0/A hepatocellular carcinoma (HCC) and clinically significant portal ... We retrospectively reviewed the medical records of 647 HCC patients in BCLC stage 0/A who were treated at five centers between January 2010 and January 2019. Among these patients, 434 underwent laparo... Among the 434 patients who underwent laparoscopic hepatectomy, 186 had CSPH and 248 did not. The Kaplan-Meier analysis showed that the OS and RFS rates were significantly worse in the CSPH group befor... CSPH has a negative impact on the prognosis of BCLC stage 0/A HCC patients after laparoscopic hepatectomy. Laparoscopic hepatectomy is still recommended for treatment, but careful patient selection is...

[Translated article] Clinical and Epidemiological Characteristics of Patients Being Treated for Scabies in Spain: Opportunities for Improvement - A Multicenter Cross-Sectional CLINI-AEDV Study.

Several studies support the hypothesis that scabies is on the rise in Spain. There are also concerns about the possible development of resistance to treatment and an increase in atypical presentations... We conducted an observational, cross-sectional, multicenter study of data collected prospectively in April and May 2023 using the CLINI-AEDVp platform created by the Spanish Academy of Dermatology and... Participating dermatologists from 31 hospitals in 15 of Spain's autonomous communities recorded 186 cases of active scabies (51% in women) during the study period. A diagnostic certainty level of A, B... In a high proportion of scabies cases, the patient has already received treatment. In those cases, we observe several remediable shortcomings that could explain why some of these treatments fail. Reme...

Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy: multicenter retrospective cohort study.

The high false negative rate (FNR) associated with sentinel lymph node biopsy often leads to unnecessary axillary lymph node dissection following neoadjuvant chemotherapy (NAC) in breast cancer. The a... A total of 1038 patients were enrolled, comprising 234 patients in the primary cohort, 723 patients in three external validation cohorts, and 81 patients in the prospective cohort. For predicting axil... The machine learning stacking model achieved excellent performance in detecting ALN metastasis, with an area under the curve (AUC) of 0.958 in the primary cohort, 0.881 in the external validation coho... Our study highlights the potential of AI-assisted surgery as a valuable tool for evaluating ALN response to NAC, leading to a reduction in unnecessary axillary lymph node dissection procedures....

Incidence, risk factors and outcome of acute kidney injury in critically ill COVID-19 patients in Tyrol, Austria: a prospective multicenter registry study.

Acute kidney injury is a frequent complication in critically ill patients with and without COVID-19. The aim of this study was to evaluate the incidence of, and risk factors for, acute kidney injury a... This multicenter prospective registry study included adult patients with a SARS-CoV-2 infection confirmed by polymerase chain reaction, who were treated in one of the 12 dedicated intensive care units... In total, 1042 patients were included during the study period. The median age of the overall cohort was 66 years. Of the included patients, 267 (26%) developed acute kidney injury during their intensi... As in non-COVID-19 patients, acute kidney injury is clearly associated with increased mortality in critically ill COVID-19 patients. Among known risk factors, invasive mechanical ventilation has been ...

Artificial intelligence-enhanced 12-lead electrocardiography for identifying atrial fibrillation during sinus rhythm (AIAFib) trial: protocol for a multicenter retrospective study.

Atrial fibrillation (AF) is the most common arrhythmia, contributing significantly to morbidity and mortality. In a previous study, we developed a deep neural network for predicting paroxysmal atrial ... We will conduct a retrospective cohort study of more than 50,000 12-lead ECGs from November 1, 2012, to December 31, 2021, at 10 Korean University Hospitals. Data will be collected from patient record... This study will advance PAF prediction based on AI-enhanced ECGs. This approach is a novel method for risk stratification and emphasizes shared decision-making for early detection and management of pa... The study findings will be published in peer-reviewed publications and disseminated at national and international conferences and through social media. This study was approved by the institutional rev... [cris.nih.go.kr], identifier (KCT0007881)....

Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.

In recent years, immune checkpoint inhibitors have been used in combination with tyrosine kinase inhibitors and local therapies, creating a new era in treating hepatocellular carcinoma (HCC) with port... This study enrolled patients receiving triple therapy at four institutions between August 2018 and April 2022. Patient characteristics and course of treatment were extracted from patient records. Tumo... Median follow-up duration was 18 (4.0-26.3) months. Overall, 41 patients with HCC and Vp4 receiving first-line triple therapy were enrolled. The intrahepatic tumor objective response rate was 68.3%. T... TACE plus lenvatinib and PD-1 inhibition was effective and tolerable for treating unresectable HCC with Vp4, with a high tumor response rate and favorable prognosis....

The impact of a structured assessment and decision tool (I-DECIDED®) on improving care of peripheral intravenous catheters: A multicenter, interrupted time-series study.

Peripheral intravenous catheters are the most widely used invasive device in hospitals but have serious risks.... To determine if a structured assessment and decision tool (I-DECIDED®) improves daily peripheral intravenous catheter assessment and care decisions.... Prospective, interrupted time-series study.... Seven adult inpatient wards in three Australian hospitals.... 825 adults with 867 peripheral intravenous catheters.... Between August 2017 and December 2018, peripheral intravenous catheter assessments and chart audits were undertaken with informed patient consent. Following a 4-month pre-intervention period (with 2-w... Of 2055 patients screened, 1175 (57.2%) had a peripheral intravenous catheter, and 825 patients (867 catheters) consented and were included in the final analysis. Device utilization increased from 42.... Implementation of a comprehensive device assessment and decision tool (I-DECIDED®) reduced idle catheters and catheter complications, despite higher device utilization. Dressing quality improved but w... ACTRN12617000067370. Date of registration 13 January 2017. Date of first data collection 3rd August 2017.... #IDECIDEDassessment reduces prevalence of idle peripheral catheters and device complications....

A Longitudinal MRI-Based Artificial Intelligence System to Predict Pathological Complete Response After Neoadjuvant Therapy in Rectal Cancer: A Multicenter Validation Study.

Accurate prediction of response to neoadjuvant chemoradiotherapy is critical for subsequent treatment decisions for patients with locally advanced rectal cancer.... To develop and validate a deep learning model based on the comparison of paired MRI before and after neoadjuvant chemoradiotherapy to predict pathological complete response.... By capturing the changes from MRI before and after neoadjuvant chemoradiotherapy in 638 patients, we trained a multitask deep learning model for response prediction (DeepRP-RC) that also allowed simul... Multicenter study.... We retrospectively enrolled 1201 patients diagnosed with locally advanced rectal cancer who underwent neoadjuvant chemoradiotherapy before total mesorectal excision. Patients had been treated at 1 of ... The main outcome was the accuracy of predicting pathological complete response, measured as the area under receiver operating curve for the training and validation data sets.... DeepRP-RC achieved high performance in predicting pathological complete response after neoadjuvant chemoradiotherapy, with area under the curve values of 0.969 (0.942-0.996), 0.946 (0.915-0.977), 0.94... This study was limited by its retrospective design and absence of multiethnic data.... DeepRP-RC could be an accurate preoperative tool for pathological complete response prediction in rectal cancer after neoadjuvant chemoradiotherapy.... ANTECEDENTES:La predicción precisa de la respuesta a la quimiorradioterapia neoadyuvante es fundamental para las decisiones de tratamiento posteriores para los pacientes con cáncer de recto localmente...

Infarct severity and outcomes in ST-elevation myocardial infarction patients without standard modifiable risk factors - A multicenter cardiac magnetic resonance study.

Standard modifiable cardiovascular risk factors (SMuRFs) are well-established players in the pathogenesis of ST-elevation myocardial infarction (STEMI). However, in a significant proportion of STEMI p... To assess the infarct characteristics at myocardial-tissue level and subsequent clinical outcomes in SMuRF-less STEMIs.... This multicenter, individual patient-data analysis included 2012 STEMI patients enrolled in four cardiac magnetic resonance (CMR) imaging studies conducted in Austria, Germany, Scotland, and the Nethe... No SMuRF was identified in 185 patients (9%). These SMuRF-less patients were older, more often male, had lower TIMI risk score and pre-interventional TIMI flow, and less frequently multivessel-disease... In this large individual patient-data pooled analysis of low-risk STEMI patients, infarct characteristics and clinical outcomes were not different according to SMuRF status....

MesenchymAl stromal cells for Traumatic bRain Injury (MATRIx): a study protocol for a multicenter, double-blind, randomised, placebo-controlled phase II trial.

Traumatic brain injury (TBI) is a significant cause of death and disability, with no effective neuroprotective drugs currently available for its treatment. Mesenchymal stromal cell (MSC)-based therapy... The study will be conducted in two steps. Step 1 will enrol 42 patients, randomised in a 1:1:1 ratio to receive 80 million MSCs, 160 million MSCs or a placebo to establish safety and identify the most... Overall, the MATRIx trial is a critical step towards developing an effective treatment for TBI, which could significantly improve the lives of millions worldwide affected by this debilitating conditio...